Glycine and its synaptic interactions
Functional and clinical implications
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
GLOSSARY
- Cys=
- cysteine;
- GABA=
- γ-aminobutyric acid;
- GlyR=
- glycine receptor;
- KCC2=
- K+, Cl− cotransporter 2;
- NKH=
- nonketotic hyperglycinemia;
- NMDAR=
- NMDA receptor;
- VGAT=
- vesicular GABA transporter;
- VIAAT=
- vesicular inhibitory amino acid transporter.
Glycine is a major neurotransmitter of inhibitory neurons in the spinal cord and brainstem. In many of these neurons, glycine coexists with γ-aminobutyric acid (GABA). The synaptic availability of glycine is controlled by 2 different transporters, and its postsynaptic effects are mediated by a specific chloride (Cl−) channel receptor. In the adult nervous system, glycine exerts fast postsynaptic inhibition that is important for control of excitability of motor neurons, auditory processing, pain transmission in the dorsal horn, and other functions. Corelease of GABA may affect the temporal profile of the postsynaptic effects of glycine. Glycine is also a coagonist of glutamate on NMDA receptors (NMDARs). Studies in vitro and in knockout mouse models have provided insight on the complex synaptic interactions among glycine, GABA, and glutamate, and on the consequences of impaired regulation of glycinergic transmission in the nervous system. Excessive synaptic levels of glycine may explain the manifestations of nonketotic hyperglycinemia, whereas loss-of-function mutations impairing glycinergic signaling have been linked to familial hyperekplexia. Autoimmune disorders affecting the glycine receptor (GlyR) complex may also result in excessive motoneuron excitability. Pharmacologic blockade of a glycine transporter may constitute a novel approach to increase NMDAR activity in schizophrenia. Many of these topics have been recently reviewed.1,–,9
GLYCINE AS A NEUROTRANSMITTER: VESICULAR STORAGE AND TRANSPORT MECHANISM
Synthesis and storage.
Glycine is the primary neurotransmitter of many inhibitory interneurons in the spinal cord and brainstem, including the ventral horn and motor cranial nerve nuclei, dorsal horn and trigeminal nuclei, and auditory and vestibular systems; it also mediates inhibitory effects of some amacrine cells and Golgi cells of the cerebellum.1 Glycine also has an essential role in intermediate metabolism; for example, it is the precursor to the one-carbon pool of folic acid intermediates that are fundamental to many synthetic reactions. Glycine is catabolized via the glycine cleavage system, a group …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Alert Me
Recommended articles
-
Clinical Implications of Neuroscience Research
Dorsal horn circuitryComplexity and implications for mechanisms of neuropathic painEduardo E. Benarroch et al.Neurology, February 17, 2016 -
Clinical Implications of Neuroscience Research
Cation-chloride cotransporters in the nervous systemGeneral features and clinical correlationsEduardo E. Benarroch et al.Neurology, February 18, 2013 -
Article
Novel clinical features of glycine receptor antibody syndromeA series of 17 casesAmanda L. Piquet, Murtaza Khan, Judith E.A. Warner et al.Neurology: Neuroimmunology & Neuroinflammation, July 01, 2019 -
ARTICLES
Involvement of glycine and GABAA receptors in the pathogenesis of spinal myoclonusIn vitro studies in the isolated neonatal rodent spinal cordEly S. Simon et al.Neurology, October 01, 1995